Tildrakizumab: Phase III data

Top-line data from the double-blind, Phase III MK-3222-011 trial in about 1,090 patients with moderate to severe plaque psoriasis showed that 100 and 200 mg doses of subcutaneous tildrakizumab given at weeks 0 and 4 then

Read the full 360 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE